Showing results (181-190 of 250) with videos related to
Sort By:
Pageof 25
Computer Methods and Programs in Biomedicine|October 1, 1994
Biomagnetic methodologies for the noninvasive investigations of the human brain (MAGNOBRAIN)G Anogianakis, G F Harding, M Peters, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|December 20, 2005
Neuropathological changes in ten cases of neuronal intermediate filament inclusion disease (NIFID): a study using alpha-internexin immunohistochemistry and principal components analysis (PCA)R A Armstrong, E Kerty, K Skullerud, et al.Medical Decision Making : an International Journal of the Society for Medical Decision Making|April 1, 1995
Decision analysis for lower-third-molar surgeryM Brickley, E Kay, J P Shepherd, et al.Dementia (Basel, Switzerland)|July 1, 1996
The use of multivariate methods in the identification of subtypes of Alzheimer's disease: a comparison of principal components and cluster analysisR A Armstrong, L Wood, D Myers, et al.Revista De Biologia Tropical|July 23, 2004
Distribution of the cyanophyte Trichodesmium (Oscillatoriaceae) in the eastern Caribbean Sea: influence of the Orinoco RiverA Navarro, J E Corredor, J Morell, et al.International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology|May 1, 1994
Topographic mapping of the pattern onset evoked magnetic response to stimulation of different portions of the visual fieldG F Harding, C Degg, S J Anderson, et al.Electroencephalography and Clinical Neurophysiology|June 2, 1998
Cortical localisation of magnetic fields evoked by oesophageal distensionP L Furlong, Q Aziz, K D Singh, et al.British Journal of Pharmacology|April 1, 1995
Characterization of the PGE receptor subtype mediating inhibition of superoxide production in human neutrophilsE Talpain, R A Armstrong, R A Coleman, et al.Neuroscience Letters|January 1, 2004
Temporal lobe pathology of human patients with neurofilament inclusion diseaseN J Cairns, E Jaros, R H Perry, et al.Eye (London, England)|November 23, 2006
First-line therapy with latanoprost 0.005% results in improved ocular circulation in newly diagnosed primary open-angle glaucoma patients: a prospective, 6-month, open-label studyD Gherghel, S L Hosking, I A Cunliffe, et al.Pageof 25